Trinity Biotech PLC（TRIB）のニュースとイベントTRIBTrinity Biotech PLC

Trinity Biotech Signs Strategic Collaboration Agreement with Latch Medical

Trinity Biotech announced a strategic collaboration agreement with Latch Medical. The collaboration is intended to combine data streams from Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's advanced drug delivery technologies to evaluate the development of precision therapeutic solutions for diabetes, obesity and other metabolic conditions. The companies will explore how real-time metabolic data generated by CGM+ can be used to help guide and optimize therapeutic delivery, creating the potential for more personalized and responsive treatment approaches. As part of the collaboration, Trinity Biotech has also agreed in principle to make a strategic equity investment in Latch Medical, which has previously attracted strategic investment from established participants in the global drug delivery industry. Trinity Biotech's planned investment reflects its belief in the potential importance of precision intradermal delivery technologies within next-generation metabolic health solutions.

Trinity Biotech Officially Terminates Equity Purchase Agreement with Yorkville

Trinity Biotech announced that it has formally provided notice of termination to YA II PN, an affiliate of financing partner Yorkville Advisors Global, in respect of its standby equity purchase agreement, or SEPA, for an equity line of credit facility. The company has determined that it does not intend to make any further use of the SEPA. Accordingly, termination of the equity line of credit facility reflects the company's current financing strategy.